{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[13,2,13,3],[14,2,14,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911034572803321"]
[null,null,"Autore",null,"Spangenberg Thomas"]
[null,null,"Titolo",null,"Praziquantel : Discovery and Development of an Anthelmintic Drug / / edited by Thomas Spangenberg"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2026"]
[null,null,"ISBN",null,"3-031-97397-6"]
[null,null,"Edizione",null,"[1st ed. 2026.]"]
[null,null,"Descrizione fisica",null,"1 online resource (318 pages)"]
[null,null,"Collana",null,"Biomedical and Life Sciences Series"]
[null,null,"Disciplina",null,"571.999"]
[null,null,"Soggetti",null,"Parasitology"]
[{"$nulls":4},"Pharmacology"]
[{"$nulls":4},"Pharmacovigilance"]
[{"$nulls":4},"Drug Safety and Pharmacovigilance"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Chapter 1: A Brief History of the Pharmaceutical Industry -- Chapter 2: The Parasite`s Life Cycle and the Patient -- Chapter 3: The Medical Need for Patients with Schistosomiasis -- Chapter 4: From Small Molecule to Drug Product, the Chemical Journey of Praziquantel -- Chapter 5: The Molecular Drug Target of Praziquantel -- Chapter 6: In Vitro and In Vivo Activity of Praziquantel Against Schistosome Worms -- Chapter 7: In Life Behaviour of Praziquantel & Relationship Between Drug Exposure and Effect -- Chapter 8: Nonclinical safety of Praziquantel -- Chapter 9: Controlled Human Schistosoma mansoni Infection Model & Biomarkers -- Chapter 10: Clinical efficacy of Praziquantel on Schistosoma Infections -- Chapter 11: Regulators’ Viewpoint -- Chapter 12: Proprietary Aspects of Praziquantel."]
[null,null,null,"Sommario/riassunto","This open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights. The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert "]
[{"$nulls":4},"commentary, and clear summaries enhance the educational value of the text. Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases."]